Compare Citius Pharmaceuticals Inc (CTXR) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Krispy Kreme Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Krispy Kreme Inc trades at $2.96 (market cap $521.37M). The key difference: Krispy Kreme Inc is far larger — about 38.3× Citius Pharmaceuticals Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Krispy Kreme Inc for 46 Days on average.
| CTXR | DNUT | |
|---|---|---|
Market Cap | $13.62M | $521.37M |
Volume | 132,438 | 2,293,015 |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $4.70 |
52-Week Low | $0.48 | $2.87 |
Typical Hold Time | 17 Days | 46 Days |
Enterprise Value | $3.79M | $1.76B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Krispy Kreme (DNUT) trades at $2.945, up 0.86% with a bullish technical signal despite mixed earnings. The company shows strong gross margins (75.19%) but negative net income (-$515.77M for 2025) and declining revenue trends. Analyst sentiment is positive with 50% buy ratings, though recent news highlights ongoing legal investigations into fiduciary duties.
Investment outlook remains cautious due to profitability challenges and legal overhangs, offset by low valuation multiples (P/S 0.35) and product innovation. Key risks include sustained losses, debt burden, and litigation outcomes. Upside depends on margin improvement and successful new launches.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
